In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Buy GHK Cu 50mg UK Copper Peptide Starter UK Peptide Lab Cagri 10mg Research Peptide Regen Peptides UK Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet GHK Cu 50mg vial